Fremont, Calif.
510-585-2200
www.aryx.com
Exchange and Ticker: Nasdaq: ARYX
Filing Range: 5M shares @ $14.00 to $16.00
Offering Price: $10.00
Close on First Day: $9.00
Offering Size: $50.00M
Shares Outstanding: 17,536,645
Underwriters: Morgan Stanley
CoManager: CIBC WorldMarkets Inc./ Jefferies & Co. Inc./ Leerink Swann & Co.
Company Counsel: Cooley Godward
Manager Counsel: Davis Polk & Wardwell
Auditor: Ernst & Young LLP
Market Capitalization on 11/30/07: $131.52M
Close price at current month end: $7.50
COMPANY DESCRIPTION
Company aims to enhance drug safety using the retro-metabolic concept. Its products are conceived around validated targets, using therapeutic agents. This method is designed to produce inherently safer drugs, addressing a medical need of the pharmaceutical industry. Competitors include Novartis Pharmaceuticals Corp., Alizyme plc, Johnson & Johnson, Bayer AG, Pfizer Inc. and Eli Lilly.
VENTURE BACKERS
Ascent Biomedical Ventures, ATEL Ventures Inc., Itochu Corp., JAFCO Co., JAFCO Investment, Merlin Nexus, Montreux Equity Partners, MPM Capital, OrbiMed Advisors.
Source: Thomson Financial